Zimbabwe has turned down a substantial American health deal valued at 367 million US dollars (272 million pounds) spanning five years over the United States' insistence on sensitive information.
This move was revealed after a internal memorandum from December was leaked, revealing that Head of State Emmerson Mnangagwa felt the deal was "unbalanced".
An official spokesman has since explained that the United States was demanding access to biological samples for research and commercial purposes while refused to guarantee the resulting advantages from any future treatments.
"We must now begin the difficult and regrettable task of winding down our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had donated over $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for more talks to find a deal acceptable to all parties so the nation's vital HIV programme can be sustained.
Wider Implications
Zimbabwe's decision follows a comparable situation in neighbouring Kenya, where a high court halted a similar health funding agreement following concerns were raised about the safety of Kenyans' health data.
Since returning to the presidency recently, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the American government, but Trump stated its expenditure was "wasteful" and his administration was seeking government-to-government agreements to enhance transparency and responsibility.
According to statements, 16 nations in Africa have so far agreed to similar agreements, constituting over $18.3bn in new funding.
Details of the Rejected Agreement
This assistance for Zimbabwe would have supported "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this collaboration would have delivered extraordinary benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently on HIV treatment through American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"Zimbabwe was being asked to provide its genetic material and health information indefinitely, with no corresponding guarantee of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that shared data," he stated.
"Put simply, our nation would supply the basic resources for medical research without any certainty that the resulting innovations would be available to our people should a new pandemic emerge."
National Interest and International Frameworks
He also pointed out that the American exit from the global health body and its pursuit of one-on-one health agreements were undermining frameworks previously established through the international organization.
Mangwana cited its Pathogen Access and Benefit Sharing system created to manage potential pandemics.
"This framework is intended to ensure that when a nation contributes its information, the resulting advantages – including medicines and cures – are shared equitably, not commercialised exclusively by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We are open to further dialogue with our US partners on how future co-operation could be structured in a way that honours the independence and interests of each country."
Medical Community Response
Medical experts said it acknowledged the government's concerns, but recommended that talks should continue given that a large portion of the country's Aids initiatives relied on foreign aid.
"In cases where specific concerns exist, such as those relating to data governance or agreement terms, these can frequently be addressed via detailed discussion and mutually agreed protections," it said.
The situation underscores the complex debate between accepting vital international aid and protecting a country's data in an ever more data-driven world.